[7:45-8:00] Welcome to IWWM-12

Christian Buske, Jeffrey Matous, and Steven Treon [Workshop Organizers]

 

[8:00-9:00] Session I 

WM Predisposition

Romanos Sklavenitis-Pistofidis, Gareth Morgan [Chairs]

 

Findings from the iSTOP Study

Sigurdur Kristinsson, Landspitali-The National University Hospital of Iceland, Iceland

 

Large scale GWAS illuminates disease aetiology for WM and LPL

Sonja Berndt, National Institutes of Health, USA

 

Genome-Wide DNA Methylation Analysis Reveals Epigenetic Influence on Intracellular and Cytokine Signaling Pathways in WM Compared to IgM-MGUS

Stephen Ansell, Mayo Clinic, United States

 

Multi-Omics for Deciphering Mechanisms of Progression in Pre-Malignant IgM Gammopathies

Simone Ferrero, Università di Torino/Ematologia Universitaria, Italy

 

[8:45] Panel Discussion, All Session I Speakers

 

[9:00-10:00] Session II

WM/LPL Genomics I

Bruno Paiva, Christopher Oakes [Chairs]

 

Using Mutographs to Define the Molecular Landscape and Cell of Origin of WM

Gareth Morgan, N.Y.U. Grossman School of Medicine, United States

 

Aberrant Expression of Spliced WNK2 Is an Early event in MYD88-Mutated WM that Activates ERK 1/2

and supports Tumor Growth

Maria Luisa Guerrera, Dana Farber Cancer Institute, United States

 

Molecular Clusters and Tumor-immune Drivers of IgM Monoclonal Gammopathies

Patrizia Mondello, Mayo Clinic, United States

 

Clonal Architecture and Evolutionary History of WM at the Single-cell Level

Cristina Jiménez, Hospital Universitario de Salamanca, Spain

 

Chromatin Accessibility Landscape and Regulatory Networks of IgM monoclonal Gammopathies

David Moreno, Hospital Clínic de Barcelona, Universitat de Barcelona, Spain

 

[9:50] Panel Discussion, All Session II Speakers

 

[10:00-10:30] Mid-Morning Break & Networking

 

[10:30-11:30] Session III

WM/LPL Genomics II

Nikhil Munshi, Marzia Varettoni [Chairs]

 

Harnessing Epigenetic Signatures for Classification of WM

Christopher Oakes, Ohio State University, James Comprehensive Cancer Center, United States

 

Landscape of IgH Gene Repertoire and Clinical Relevance to LPL/WM

Mu Hao, Chinese Academy of Medical Sciences, Institute of Hematology and Blood Diseases Hospital, China

 

Single Cell multi-omics for minimally invasive assessment of Treatment efficacy in WM

Bruno Paiva, Clinica Universidad de Navarra, Spain

 

Clonal Hematopoiesis in Patients with WM

Adam Sperling, Dana Farber Cancer Institute, United States

 

[11:15] Panel Discussion, All Session III Speakers

 

[11:30-12:30] Session IV

Single Cell RNA Analysis

Irene Ghobrial/Bruno Paiva [Chairs]

 

Single-Cell RNA Analysis of Tumor and Immune Cells in Asymptomatic WM

Romanos Sklavenitis-Pistofidis, Harvard Medical School, Broad Institute of MIT & Harvard , United States

 

Single-Cell RNA Analysis of MYD88 Mutated and Wild-type WM

Tina Bagratuni, National & Kapodistrian Univ., Sch of Med., Univ. of Athens, Greece

 

Single-Cell RNA reveals Stem Cell like Subsets in WM Progression

Xinxin Cao, Peking Union Medical College Hospital, China

 

Single-Cell RNA reveals Tumor Heterogeneity and Immunosuppressive Microenvironment in WM

Hao Sun, Dana Farber Cancer Institute, United States

[12:15] Panel Discussion, All Session IV Speakers

 

[12:30-13:30] LUNCH

 

[13:30-14:30] Session V

Keynote Lectures

 

Sub-typing WM by Multi-Omic Analysis

Keynote Moderator: Christian Buske

Keynote Speaker: Zachary Hunter, Dana Farber Cancer Institute, United States

[13:50] Topic Discussion

 

BM Stromal Cells and Transcriptional Regulation: Lessons for WM

Keynote Moderator: Christian Buske

Keynote Speaker: Nikhil Munshi, Dana Farber Cancer Institute, United States

[14:20] Topic Discussion

 

[14:30-15:15] Session VI

Molecular Diagnostics in WM

Ramón García Sanz/Roman Hajek [Chairs]

 

Clinical Implications of Genomic Profiling

Carlos Fernandez de Larrea Rodríguez, Hospital Clínic de Barcelona, Universitat de Barcelona, Spain

 

Digital Droplet (ddPCR) for Detection of MYD88 L265P Variants

Daniela Drandi, Università di Torino/Ematologia Universitaria, Italy

 

Molecular Remissions is an Independent Predictor of Progression-Free Survival in WM

Marzia Varettoni, Fondazione IRCCS Policlinico San Matteo, Italy

 

[15:00] Panel Discussion, All Session VI Speakers

 

[15:15-15:45] Mid-Afternoon Break & Networking

 

[15:45-16:30] Session: VII

Keynote Lecture

 

MYD88 and CXCR4 Signaling Cascades

Keynote Moderator: Adrian Wiestner, NHLBI, NIH, Hematology Branch, United States

Keynote Speaker: Steven Treon, Dana Farber Cancer Institute, United States

[16:15] Topic Discussion

 

[16:30-17:45] Session: VIII

Plenary Session I

Gareth Morgan, Zachary Hunter [Chairs]

 

Genomic Landscape of IgM MGUS and Stable vs. Progressive Asymptomatic WM Patients

Tina Bagratuni, National & Kapodistrian Univ., Sch of Med., Univ. of Athens, Greece

 

Single Cell Multi-omics for Phenotypic Characterization of Clonal B Cells in Patients with IGM MGUS and WM

Carmen González Díaz-Cano, Universidad de Navarra, Spain

 

Characterization of WM/LPL using Single Cell Transcriptomic Analysis

Minghao Dang, MD Anderson Cancer Center, United States

 

A Multi-omic Analysis of WM Defines Three Subtypes of Disease

Dylan Gagler, Perlmutter Cancer Center, NYU Langone Health, United States

 

Determining the Mutational Landscape of WM by Liquid Biopsy: Results of the ECWM-2 Trial

Philipp Nakov, Universitätsklinikum Schleswig-Holstein, Germany

 

[17:40] Panel Discussion, All Session VIII Speakers

 

[19:00] Opening Ceremonies and Awards Presentation

[18:15] Buses begin departing from the Hotel

 

• Keynote Speaker: BeiGene, Inc.
• Presentation of Jan Gosta Waldenstrom Awards
• Presentation of Robert A. Kyle Awards

[8:00-9:00] Session IX

Tumor Immune Microenvironment

Stephen Ansell & José Martínez Climent [Chairs]

 

Dysfunctions of Innate and Adaptive Immune Tumor Microenvironment in WM

Jana Jakubikova, Cancer Research Institute, Biomedical Research Center SAS, Slovakia

 

Deciphering the Immune Microenvironment in WM

Aldo Roccaro, ASST Spedali Civili di Brescia, Italy

 

Analysis of Molecular and Microenvironment Landscape and Its Role in Drug Resistance in WM

Damien Roos-Weil, Sorbonne University, Groupe hospitalier Pitié-Salpêtrière, France

 

The Characterization and Modeling of MYD88 L265P Mutation and Chromosome 6q Deletion in Murine B-Cells

Ruben Carrasco, Dana Farber Cancer Institute, United States

 

[8:45] Panel Discussion, All Session IX Speakers

 

[9:00-10:00] Session X

Chemoimmunotherapy in WM I

Shirley D’Sa & M.J. Kersten [Chairs]       

 

Dexamethasone, Rituximab, and Cyclophosphamide (DRC) versus Bortezomib-DRC (B-DRC) in WM

Christian Buske, University Hospital Ulm, Experimental Cancer Research & Dept. Of Internal Medicine III, Germany

 

Long-term Outcomes of FILO Study: Frontline Benda-Rituximab in WM

Veronique Leblond, Hôpital Pitié Salpêtrière,France

 

Multicenter Observational Study of Benda-Rituximab vs. RCD

Francesco Autore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Italy

 

Long-term Outcomes of 678 patients with Symptomatic WM

Elham Askari, Hospital Universitario Fundación Jiménez Díaz, Spain

 

[9:45] Panel Discussion, All Session X Speakers

 

[10:00-10:30] Mid-Morning Break & Networking

 

[10:30-11:30] Session XI

Chemoimmunotherapy in WM II

Veronique Leblond & Meletios Dimopoulos [Chairs]

 

Role of Proteasome Inhibitors in WM

M.J. Kersten, University of Amsterdam, The Netherlands

 

Management of Transformed WM

Eric Durot, Hopital Robert Debre, Hematologie Clinique, France

 

Final Analysis of Innovative Study; Ibrutinib Rituximab vs. Placebo/Rituximab: Clinical and Genomic Findings

Christian Buske, University Hospital Ulm, Experimental Cancer Research & Dept. Of Internal Medicine III, Germany

 

Comparative Outcomes of Benda-R vs. Ibrutinib in Frontline WM

Jithma Abeykoon, Mayo Clinic, United States

 

[11:15] Panel Discussion, All Session XI Speakers

 

[11:30-12:30] Session XII

BTK-Inhibitors in WM I

Stathis Kastritis & Marek Trneny [Chairs]

 

Long Term Findings of ASPEN Study: Clinical Outcomes

Meletios Dimopoulos, University of Athens School of Medicine, Greece

 

Long Term Updates on Ibrutinib and Venetoclax in Frontline WM

Jorge Castillo, Dana Farber Cancer Institute, United States

 

ECWM-2 Prospective Study

Christian Buske, University Hospital Ulm, Experimental Cancer Research & Dept. Of Internal Medicine III, Germany

 

BRAWM Study: Bendamustine, Rituximab and Acalabrutinib in Frontline WM

Neil Berinstein, Odette Cancer Center, Canada

 

[12:15] Panel Discussion, All Session XII Speakers

 

[12:30-13:30] IWWM12 LUNCH

Moravia Hall

 

[12:30-13:30] Young Investigator Mentoring LUNCH

Studio G

 

[13:30-14:30] Session: XIII

BTK-Inhibitors in WM II

Alessandra Tedeschi & Ranjana Advani [Chairs]

 

Pirtobrutinib in Relapsed/Refractory WM: Results from Bruin Study

1. Lia Palomba, Memorial Sloan-Kettering Cancer Center, United States

 

Tirabrutinib in Symptomatic WM and Bing-Neel Syndrome (BNS)

Naohiro Sekiguchi, National Hospital Organization Disaster Medical Center ,Japan

 

Orelabrutinib in Relapsed/Refractory WM: Long-Term Follow-up

Xinxin Cao, Peking Union Medical College Hospital, China

 

Prospective Study of Acalabrutinib and Rituximab in Symptomatic Anti-MAG mediated IgM Peripheral Neuropathy

Shayna Sarosiek, Dana Farber Cancer Institute, United States

 

[14:15] Panel Discussion, All Session XIII Speakers

 

[14:30-15:00] Session XIV

Keynote Lecture

 

Utility of MRD in Clinical Care and New Drug Development in Myeloma

Keynote Moderator: Steven Treon, Dana Farber Cancer Institute, United States

Keynote Speaker: Kenneth Anderson, Dana Farber Cancer Institute, United States

[14:50] Topic Discussion

 

[15:00-16:00] Session: XV

BTK-I Intolerant and Resistant Disease

Carlos Fernández de Larrea Rodríguez & Prashant Kapoor [Chairs]

 

Dose reduction following ibrutinib intolerance in WM patients

Shayna Sarosiek, Dana Farber Cancer Institute, United States

 

Zanubrutinib for Patients intolerant of other BTK-I

Mazyar Shadman, Fred Hutchinson Cancer Research Center, United States

 

Bortezomib for Patients Failing BTK-I

Jahanzaib Khwaja, University College London Hospitals, United Kingdom

 

BGB-16673 BTK Degrader

John Seymour, Peter MacCallum Cancer Centre, Australia

 

[15:45] Panel Discussion, All Session XV Speakers

 

[16:00-17:00] Session XVI

Keynote Lectures

 

Genomic Evolution and Resistance Following BTK-Inhibitors in CLL:

Lessons for Sequencing and Managing BTK-Inhibitors

Keynote Moderator: Jeffrey Matous, Colorado Blood Cancer Institute, United States

Keynote Speaker: Jennifer Brown, Dana Farber Cancer Institute, United States

[16:20] Topic Discussion

 

Role of BTK Inhibitors as Facilitators of Cellular Immunotherapies

Keynote Moderator: Jeffrey Matous, Colorado Blood Cancer Institute, United States

Keynote Speaker: Adrian Wiestner, NHLBI, NIH, Hematology Branch, United States

[16:50] Topic Discussion

 

[17:00-19:00] Session XVII

IWWM12 Poster Highlights

Andrew Branagan & Josephine Vos [Chairs]

Poster Session & Reception

Moravia Hall

 

[19:30] Faculty Dinner Reception

[19:00] Departure in the Hotel Lobby

 

[8:00-9:00] Session XVIII

Special Topics Lectures

Moshe Gat & Claudio Cerchione [Chairs]

 

Management of IgM De-Myelinating neuropathy

Speaker: Shirley D’Sa, UC London Hospitals NHS, United Kingdom

 

Management of Bing Neel Syndrome

Speaker: Monique Minnema, University of Utrecht, The Netherlands

 

Diagnostic Workup and Management of WM-related Amyloid

Speaker: Giampaolo Merlini, University of Pavia, Italy

 

Diagnostic Workup and Management of Monoclonal IgM-related Cold Agglutinin Disease

Speaker: Josephine Vos, University of Amsterdam, The Netherlands

 

[8:45] Panel Discussion, All Session XVIII Speakers

 

[9:00-10:00] Session: XIX

Plenary Session II

Ranjana Advani & Meletios Dimopoulos [Chairs]

 

Phase I Study of the Novel BCL2 Inhibitor Sonrotoclax in Relapsed/Refractory WM

Ramón García Sanz, University Hospital Gregorio Marañón, Spain

 

Zanubrutinib in Bing Neel Syndrome: Efficacy and Tolerability

Anne-Marie Becking, Amsterdam UMC, The Netherlands

 

Real World Outcomes of ASCT in Patients with WM: Report from LWP EBMT

Charalampia Kyriakou, University College London Hospitals NHS Trust, United Kingdom

 

Novel BiFunctional HCK/BTK Protacs for MYD88 Mutated WM and ABC DLBCL

John M. Hatcher, Dana Farber Cancer Institute, United States

[9:45] Panel Discussion, All Session XIX Speakers

 

[10:00-10:30] Mid-Morning Break & Networking

 

[10:30-12:30] Session XX

Great Debates in WM

Eva Kimby & Irene Ghobrial [Chairs]

 

[10:30-11:00] Great Debate I

What should be the Standard for Frontline Treatment for WM?

 

For Bendamustine plus Rituximab

Christian Buske, University Hospital Ulm, Experimental Cancer Research & Dept. of Internal Medicine III,  Germany

 

For Cyclophosphamide, Dexamethasone, Rituximab (CDR)

Stathis Kastritis, National and Kapodistrian University of Athens, Greece

 

For BTK-inhibitors

Alessandra Tedeschi, A. O. Ospedale Niguarda Ca' Granda, Italy

 

[11:00-11:30] Great Debate II

What is the optimal approach for frontline use of BTK-inhibitors in WM?

 

For Limited Duration Combination Therapy with BTK-inhibitors in WM

Neil Berinstein, Odette Cancer Center, Canada

 

For Continuous Administration of BTK-inhibitors as Monotherapy

Prashant Kapoor, Mayo Clinic, United States

 

[11:30-12:00] Great Debate III

What is the next best treatment for WM patients progressing on covalent BTK-inhibitors?

For Pirtobrutinib

1. Lia Palomba, Memorial Sloan Kettering Cancer Center, United States

 

For Venetoclax

Jorge Castillo, Dana Farber Cancer Institute, United States

 

[12:00-12:30] Great Debate IV

Should TP53 Alterations be Considered for Treatment Decision Making in WM Patients?

 

Yes, TP53 Alterations should be considered

Ramón García Sanz, University Hospital Gregorio Marañón, Spain

 

No, TP53 Alterations should not considered

Shirley D’Sa, University College London Hospitals NHS Trust, United Kingdom

 

[12:30-13:30] LUNCH

 

[13:30-14:30] Session XXI

Novel Drug Development for WM

Ramón García Sanz & Lu-Gui Qiu [Chairs]

 

Development of IRAK1/IRAK4 Bifunctional PROTACs (Proteolysis-Targeting Chimeras)  for MYD88 mutated WM

Sara Buhrlage, Dana Farber Cancer Institute, United States

 

Pacritinib is a Highly Potent Inhibitor of HCK and IRAK and Triggers High Levels of Apoptosis in WM

Shirong Liu, Dana Farber Cancer Institute, United States

 

Pre-clinical Models for Prediction of Immunotherapy Outcomes and Immune Evasion

Jose Martínez Climent, University of Navarra, Spain

 

Development of BTK/BTK -IKZF Protacs for B-Cell Malignancies

Paula O’Connor, Nurix Therapeutics, Inc., United States

 

[14:15] Panel Discussion, All Session XXI Speakers

 

[14:30-15:30] Session XXII

Clinical Trials in Progress for WM I

Jeffrey Matous & Shayna Sarosiek [Chairs]

 

Carfilzomib With and Without Ibrutinib in Frontline and Relapsed/Refractory WM (CZAR-1)

Meletios Dimopoulos, University of Athens School of Medicine, Greece

 

Rainbow Trial: Ibrutinib Rituximab vs. DRC in Newly Diagnosed WM

Rebecca Auer, Barts Health NHS Trust, United Kingdom

 

Zanubrutinib plus Benda-R in Newly diagnosed WM

Shuhua Yi, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College (PUMC), China

 

Pirtobrutinib and Venetoclax in Relapsed or Refractory WM

Jorge Castillo, Dana Farber Cancer Institute, United States

 

[15:15] Panel Discussion, All Session XXII Speakers

  

[15:30-16:00] Mid-Afternoon Break & Networking

 

[16:00-17:00] Session XXIII

Clinical Trials in Progress for WM II

Efstathios Kastritis & Prashant Kapoor [Chairs]

 

Loncastuxumab in Relapsed/Refractory WM

Shayna Sarosiek, Dana Farber Cancer Institute, United States

 

Sonrotoclax for Relapsed/Refractory WM

Jeffrey Matous, Colorado Blood Cancer Institute, United States

 

Multi-center Trial of iopofosine I 131 in Relapsed/Refractory WM

Andrei Shustov, Cellectar Biosciences, United States

 

CD20-Directed CAR-T Cell

Mazyar Shadman, Fred Hutchinson Cancer Res Center, United States

 

[16:45] Panel Discussion, All Session XXIII Speakers

 

[17:00-18:00] Session XXIV

Clinical Trials in Progress for WM III

Roger Owen & Pierre Morel [Chairs] 

 

WM-NET Clinical Trial Priorities

Jorge Castillo, Dana Farber Cancer Institute, United States

Gottfried von Keudell, Beth Israel Deaconess Medical Center, United States

 

ECWM Clinical Trial Priorities

Christian Buske, University Hospital Ulm, Experimental Cancer Research & Dept. Of Internal Medicine III, Germany

 

[19:00] Dinner Reception and Closing Ceremonies

[18:15] Buses begin departing from the Hotel

• Presentation of Peter S. Bing Humanitarian Awards
• Presentation of the Young Investigator Awards
• Announcement and Welcome to IWWM-13